Faron Pharmaceuticals Drug Traumakine Fails Ph III Trial

Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), announced on 5/8/17 top line data from its pan-European Phase III INTEREST trial. The INTEREST study did not meet the Day 28 (D28) primary efficacy composite endpoint of ventilator free days and survival with Traumakine treatment. Traumakine was being studied for treatment of acute respiratory distress syndrome (ARDS).